Our results indicate that in the MASH model, increased levels of hepatic pro-inflammatory cytokines IL-1β, IL-6, and TNF-α led to increased expression and activity of TGF-β, activating the TGF-β/SMAD signaling pathway. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatohepatitis.